Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of novel benzimidazole series of potent and selective ORL1 antagonists.
Okamoto O, Kobayashi K, Kawamoto H, Ito S, Satoh A, Kato T, Yamamoto I, Mizutani S, Hashimoto M, Shimizu A, Sakoh H, Nagatomi Y, Iwasawa Y, Takahashi H, Ishii Y, Ozaki S, Ohta H. Okamoto O, et al. Among authors: mizutani s. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3278-81. doi: 10.1016/j.bmcl.2008.04.054. Epub 2008 Apr 25. Bioorg Med Chem Lett. 2008. PMID: 18468891
Optimization of benzimidazole series as opioid receptor-like 1 (ORL1) antagonists: SAR study directed toward improvement of selectivity over hERG activity.
Kobayashi K, Kato T, Yamamoto I, Shimizu A, Mizutani S, Asai M, Kawamoto H, Ito S, Yoshizumi T, Hirayama M, Ozaki S, Ohta H, Okamoto O. Kobayashi K, et al. Among authors: mizutani s. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3100-3. doi: 10.1016/j.bmcl.2009.04.022. Epub 2009 Apr 11. Bioorg Med Chem Lett. 2009. PMID: 19398200
Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate.
Satoh A, Sagara T, Sakoh H, Hashimoto M, Nakashima H, Kato T, Goto Y, Mizutani S, Azuma-Kanoh T, Tani T, Okuda S, Okamoto O, Ozaki S, Iwasawa Y, Ohta H, Kawamoto H. Satoh A, et al. Among authors: mizutani s. J Med Chem. 2009 Jul 23;52(14):4091-4. doi: 10.1021/jm900581g. J Med Chem. 2009. PMID: 19537798
The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma.
Nagata H, Tsukamoto T, Kobayashi T, Takahashi R, Okano A, Uchiyama H, Kawata E, Uoshima N, Kaneko H, Fuchida SI, Nishiyama D, Nakao M, Fujino T, Mizutani S, Shimura Y, Kuroda J. Nagata H, et al. Among authors: mizutani s. Int J Clin Oncol. 2025 Jan 7. doi: 10.1007/s10147-025-02691-8. Online ahead of print. Int J Clin Oncol. 2025. PMID: 39776016
Associations of gut microbiota with disease development, disease activity, and therapeutic effects in patients with systemic lupus erythematosus.
Nishio J, Sato H, Watanabe E, Masuoka H, Aoki K, Kawazoe M, Wakiya R, Yamada S, Muraoka S, Masuoka S, Hayashi T, Mizutani S, Yamada Z, Koshiba K, Irita I, Kanaji M, Furukawa K, Yajima N, Dobashi H, Hirose W, Ishii Y, Suda W, Nanki T. Nishio J, et al. Among authors: mizutani s. Sci Rep. 2024 Dec 30;14(1):32076. doi: 10.1038/s41598-024-83835-0. Sci Rep. 2024. PMID: 39738678 Free PMC article.
1,154 results